Use of Transplanted Regulatory T Cells Could Provide Relief for Inflammatory Diseases


Media Relations

March 18, 2015

Use of Transplanted Regulatory T Cells Could Provide Relief for Inflammatory Diseases

Rensselaer Research Team Receives $2 Million NIH Grant for Microbiome Systems Biology Research

Troy, N.Y. — With a $2 million grant from the National Institutes of Health (NIH), a team of researchers – including Rensselaer Polytechnic Institute professor Juergen Hahn – will investigate the potential of using transplanted regulatory T cells (Tregs) to reduce inflammation in diseases like inflammatory bowel disease, which currently has no known viable treatment options.

“The challenge is that the transplanted cells are not very ‘stable’ and may end up contributing to inflammation rather than combating inflammation,” said Hahn, professor, head of the Department of Biomedical Engineering, and member of the Rensselaer Center for Biotechnology and Interdisciplinary Studies. “We propose to condition the regulatory T cells by exposing them to various conditions prior to transplantation such that their stability is increased, and we expect that this will make them more potent in combating inflammation. Our goal is to transplant conditioned Tregs into a host for therapeutic inhibition of inflammation.”

The project will combine computational research at Rensselaer with research in vitro and in vivo at two Texas A&M University research laboratories. The team will create a computational model able to predict Tregs induction, function, and stability. That model will be used to develop treatment regimens that use transplanted Tregs to inhibit inflammation, providing new treatment options for a variety of diseases characterized by excessive inflammation.

Modeling and Analysis of the Role of Microbiota Metabolites in T-Cell Differentiation” is supported by a five-year grant from the NIH National Institute of Allergy and Infectious Diseases.

Hahn is an expert in systems biology and process modeling and analysis with over 80 articles and book chapters in print. He is widely recognized for his research and contributions to the field. He is a fellow of the American Institute for Medical and Biological Engineering, recipient of a CAST Outstanding Young Researcher Award from the American Institute of Chemical Engineers, winner of several foundation fellowships and best paper awards, and recipient of a Fulbright Scholarship. He is currently serving as an associate editor for the journal Control Engineering Practice and as editor for the Journal of Process Control.

Prior to joining the School of Engineering at Rensselaer in 2012, Hahn served for nine years as a faculty member at Texas A&M University. A native of Germany, he received his diploma in engineering from RWTH Aachen University in Germany, and received his master’s and doctoral degrees in chemical engineering from the University of Texas. 


For general inquiries:

About Rensselaer Polytechnic Institute

Founded in 1824, Rensselaer Polytechnic Institute is America’s first technological research university. Rensselaer encompasses five schools, over 30 research centers, more than 140 academic programs including 25 new programs, and a dynamic community made up of over 6,800 students and 104,000 living alumni. Rensselaer faculty and alumni include upwards of 155 National Academy members, six members of the National Inventors Hall of Fame, six National Medal of Technology winners, five National Medal of Science winners, and a Nobel Prize winner in Physics. With nearly 200 years of experience advancing scientific and technological knowledge, Rensselaer remains focused on addressing global challenges with a spirit of ingenuity and collaboration. To learn more, please visit